×

Access Whitepaper

First Name
Last Name
Company
Thank you!
Error - something went wrong!
   

Part 10: Unique Challenges and Opportunities for Emerging Biopharma Companies with Focused Pipelines

June 1, 2020

In this webinar, we turn our focus to the challenges unique to our innovative colleagues in the emerging biopharma space. With smaller and focused-pipeline organizations making up over 50% of clinical trials activity pre-COVID-19, these sponsors represent the potential for enormous advances in development, but also shoulder the challenges of keeping projects moving in highly concentrated pipelines during this time. Our expert speakers discuss:

  • How the agile nature of emerging biopharma has uniquely enabled them to pivot quickly and map to new methodologies to sustain and manage ongoing trials during the pandemic
  • How organizations with focused pipelines or single assets are facing development and commercial realities going forward

We’ll speak with leaders from emerging biopharma organizations with assets in different therapeutic areas and in various phases of development and commercialization; and about the evolving resources that address biopharma needs during this time.

Previous Flipbook
Part 11: The Impact of COVID-19 on Oncology Research: Immediate and Long-term Effects
Part 11: The Impact of COVID-19 on Oncology Research: Immediate and Long-term Effects

Next Flipbook
Part 9: The Challenges of Developing Vaccines and Treatments for COVID-19
Part 9: The Challenges of Developing Vaccines and Treatments for COVID-19

Request a Genetics in Clinical Trials training session

What You'll Learn